Medicskin Holdings Ltd. (8307) AI Stock Analysis

• Market Cap: HK$63.48M
• Dividend Yield: N/A
• Average Volume (3M): 24.27K
• Price to Earnings (P/E): 362.7
• Beta (1Y): 0.81
• Revenue Growth: -2.91%
• EPS Growth: 55.41%
• Country: HK
• Employees: 29
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.00
• Shares Outstanding: 396,736,000
• 10 Day Avg. Volume: 55,600
• 30 Day Avg. Volume: 24,266
• PEG Ratio: -2.10
• Price to Book (P/B): 17.59
• Price to Sales (P/S): 1.64
• P/FCF Ratio: 8.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: HK$0.17 ▼(-2.35% Downside)
• Action: Reiterated Date: 01/24/26
• Date: Action: Reiterated 01/24/26

The score is held back primarily by weak financial performance (ongoing losses, declining gross margin, and revenue contraction) and a valuation picture clouded by negative earnings. These are partly offset by relatively strong cash-flow resilience and favorable technical momentum with the price trading above major moving averages.

Positive Factors

Operating cash generation

Sustained operating cash flow growth provides durable liquidity and funds near-term operations and working capital without immediate reliance on equity raises. Over a 2–6 month horizon, stronger cash generation reduces refinancing risk and supports tactical investments or stabilization efforts despite reported losses.

Improving operational margin

A rising EBITDA margin, even modest, signals incremental operational efficiencies and cost control. If maintained, this structural improvement enhances leverage on incremental revenue, making a return to profitability more achievable over several quarters as fixed costs are absorbed and processes scale.

Disciplined capital spending

Controlled capex preserves free cash flow and extends runway, enabling the company to prioritize high-return investments. Over the medium term, capex discipline enhances financial flexibility, limiting the need for expensive external financing and improving resilience to cyclical demand swings.

Negative Factors

Ongoing losses

Multi-year net losses erode equity and limit internal funding capacity, forcing dependency on debt or external capital. This structural unprofitability constrains strategic options, increases dilution or refinancing risk, and makes sustained investment in growth or R&D harder without a credible path to consistent profits.

Declining gross margins

A steep fall in gross margin indicates material cost pressure or pricing weakness that undermines the core economics of the business. Unless structural cost reductions or price recovery occur, this compresses long-term profitability and reduces the leverage from any future revenue growth.

High financial leverage

Elevated leverage and a thin equity base heighten solvency and refinancing risks, especially with negative net income. High debt increases fixed obligations, limits strategic flexibility, and raises the probability of forced asset sales, covenant breaches, or dilutive capital raises over the coming months.

Medicskin Holdings Ltd. Business Overview & Revenue Model

Company Description

Medicskin Holdings Ltd. (8307) is a leading healthcare company specializing in advanced dermatological and aesthetic solutions. The company operates in the medical and cosmetic sectors, offering a range of products and services designed to enhance skin health and appearance. Medicskin is known for its innovative skincare products, medical devices, and aesthetic treatments, catering to both consumers and healthcare professionals.

How the Company Makes Money

null

Medicskin Holdings Ltd. Financial Statement Overview

Summary

Mixed fundamentals: persistent negative net profit margins and a sharp gross margin decline (80.2% in 2022 to 50.7% in 2025) weigh on results, alongside revenue down 8.2% (2024–2025). Offsetting this, cash flow is relatively resilient with higher operating cash flow (HKD 9.13M in 2025) and strong cash conversion despite net losses.

Income Statement

Medicskin Holdings Ltd. shows a mixed performance in its income statement. The gross profit margin has declined from 80.2% in 2022 to 50.7% in 2025, indicating increased cost pressures. The net profit margin is negative for the past three years, reflecting ongoing challenges in achieving profitability. Revenue has decreased by 8.2% from 2024 to 2025, highlighting a potential concern in growth. Despite these challenges, the company has improved its EBITDA margin from 13.8% in 2023 to 13.9% in 2025, showing some operational efficiency improvements.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 5.44 in 2025, indicating significant leverage which poses a financial risk. Stockholders' equity has decreased substantially over the years, reflecting potential financial instability. The equity ratio has also diminished to 7.3% in 2025, suggesting limited financial cushion. Return on equity is not applicable due to negative net income. These factors collectively suggest a need for careful management of financial leverage and equity to ensure long-term stability.

Cash Flow

The cash flow statement shows resilience with a strong free cash flow to net income ratio, despite negative net income, indicating efficient cash management. Operating cash flow has increased to HKD 9.13 million in 2025, supporting liquidity. However, the free cash flow has shown a marginal decrease from the previous year, and capital expenditures have been managed to support cash flow effectively. Overall, the cash flow position remains a relative strength for Medicskin Holdings Ltd.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	57.27M	45.11M	49.88M	45.54M	49.15M	41.71M
Gross Profit	18.77M	22.87M	39.39M	36.68M	42.14M	34.40M
EBITDA	6.76M	6.29M	6.78M	6.40M	14.55M	11.62M
Net Income	-1.98M	-3.38M	-3.05M	-3.54M	3.92M	953.00K
Balance Sheet
Total Assets	50.00M	57.44M	40.06M	46.37M	56.67M	58.84M
Cash, Cash Equivalents and Short-Term Investments	25.16M	17.34M	6.93M	6.37M	15.47M	30.33M
Total Debt	19.89M	22.79M	5.76M	11.93M	18.67M	6.42M
Total Liabilities	45.77M	53.25M	32.48M	35.21M	42.49M	38.85M
Stockholders Equity	4.23M	4.20M	10.95M	14.47M	17.43M	23.45M
Cash Flow
Free Cash Flow	9.44M	8.29M	9.12M	946.00K	2.33M	6.84M
Operating Cash Flow	11.42M	9.13M	10.52M	3.25M	4.29M	9.15M
Investing Cash Flow	-2.84M	-191.00K	-1.40M	-5.67M	-1.82M	-1.65M
Financing Cash Flow	-8.26M	1.48M	-7.21M	-6.74M	-17.94M	-21.03M

Medicskin Holdings Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8307, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.17, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 32.40 is Neutral, neither overbought nor oversold. The STOCH value of 92.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8307.

Medicskin Holdings Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8357	61 Neutral	HK$106.70M	-6.98	-10.31%	―	-11.68%	-71.01%
8307	58 Neutral	HK$63.48M	362.73	-19.93%	―	-2.91%	55.41%
8161	53 Neutral	HK$22.88M	-197.60	138.68%	―	-20.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2135	50 Neutral	HK$81.89M	-2.11	-64.49%	―	-20.66%	-77.84%
8437	41 Neutral	HK$19.98M	-2.29	26.12%	―	14.64%	-81.95%
8143	39 Underperform	HK$113.86M	-20.58	-132.60%	―	-30.45%	-734.38%